TROY ROHN, PHD, is a professor in the Biology Department at Boise State University. He has built a substantial academic reputation with nearly three decades of experience in neuroscience research and teaching. For his contributions to Alzheimer’s research and neurological disorders, he was recently recognized as one of the top 0.5% of scholars worldwide. Dr. Rohn received his Ph.D. in Pharmacology from the University of Washington, Seattle. He had several Postdoctoral stints including two-plus years living in Paris, France, one year at Montana State University in Bozeman, Montana, and two years at UC Irvine.
Dr. Rohn has obtained extramural funding continuously since his arrival at Boise State University including grants from NIH, AFAR, and AHAF. He has authored over 80 peer-reviewed publications, many of which address topics related to neurobiology, mental health, and treatment strategies.
In 2019, he co-established the biotech company Cognigenics. Through his work there, he explores RNA-based gene therapy for treating anxiety, while his research on the APOE4 gene functions in Alzheimer’s disease created essential knowledge for the field. He is the author of Brain Medicine.
